DB06093ExperimentalSmall molecule
ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.
- Primary indication
- Investigated for use/treatment in neurologic disorders.Curator reviewed
- Code names
- ABT-560
Which companies are running trials of ABT-560, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account